Nontuberculous mycobacteria (NTM) comprise mycobacterial species other than those of Mycobacterium tuberculosis complex and Mycobacterium leprae. Although determining the incidence and prevalence of NTM lung diseases remains challenging, recent epidemiologic reports indicate that the prevalence of NTM lung diseases is increasing, especially in many developed countries [1] [2] [3] [4] .
The Mycobacterium abscessus complex, one of the rapid-growing NTM, is an important cause of chronic pulmonary infection [2, 3, 5] . Although there is a significant variability in geographic distribution, M. abscessus complex is the most common cause of pulmonary infection worldwide among the rapid-growing NTM [6] . In South Korea, the M. abscessus complex is the second most common pathogen responsible for NTM lung diseases after the Mycobacterium avium complex (MAC) [7] . Currently, the M. abscessus complex comprises 3 different species (M. abscessus, M. massiliense, and M. bolletii) based on gene sequence analysis.
Treatment outcome for M. abscessus complex lung diseases varies significantly with culture conversion rates ranging from 40% to 80%, according to previous reports [8] [9] [10] . This variance in treatment outcome may be due to the heterogeneity in treatment strategies employed and the different proportions of M. abscessus and M. massiliense in each study population [11] . Mycobacterium abscessus is known to be more resistant to antibiotics [12] and to carry a worse prognosis compared with M. massiliense [13] [14] [15] [16] . However, few studies have reported a detailed comparison of the clinical characteristics of lung disease caused by M. abscessus and M. massiliense. The aim of this study was to elucidate the differences in progression rate, treatment outcome, and the predictors thereof between M. abscessus lung diseases and M. massiliense lung diseases. In addition, we evaluated whether susceptibility to clarithromycin correlated with treatment outcomes.
METHODS

Study Population
We retrospectively reviewed the medical records of patients diagnosed as having a lung disease caused by M. abscessus complex at the Seoul National University Hospital between 1 January 2006 and 30 June 2015. We excluded patients with a follow-up period of <6 months. The protocol of this study was approved by the institutional review board of Seoul National University Hospital (IRB No. 1511-093-721).
Microbiologic and Radiographic Evaluation
Acid-fast bacilli (AFB) smear and mycobacterial cultures were performed as recommended in the standard guidelines [17, 18] . All cultures were grown in both solid Ogawa medium and the BACTEC MGIT 960 system. NTM species were identified by gene sequence analysis of the 16S ribosomal RNA gene using the algorithm described in the Clinical and Laboratory Standards Institute (CLSI) guidelines [19] . Sequencing of the rpoB and tuf genes was performed for further identification. In particular, differentiation between M. abscessus and M. massiliense was performed based on analysis of the rpoB gene sequence [20, 21] . Antimycobacterial drug susceptibility tests were referred to the Korean Institute of Tuberculosis and performed using broth microdilution. Minimum inhibitory concentrations (MICs) of antibiotics (amikacin, cefoxitin, ciprofloxacin, clarithromycin, imipenem, moxifloxacin, and linezolid) were determined according to the CLSI guidelines as well [22] . Determining the MIC of azithromycin is difficult due to its poor solubility at high concentrations, so instead the MIC of clarithromycin was determined as being representative of this class of macrolides [23] . Isolates were regarded as susceptible if the MIC of clarithromycin was ≤2 μg/mL, and as resistant if the MIC of clarithromycin was ≥8 μg/mL. Isolates with an MIC between 2 and 8 μg/mL were regarded as having an intermediate level of resistance. Susceptibility to clarithromycin was evaluated after 3 and 14 days of incubation to detect resistance. If isolates were susceptible after 3 days of incubation and resistant after 14 days of incubation, they were considered to have inducible resistance to clarithromycin. The computed tomographic (CT) images obtained at the time of diagnosis of M. abscessus complex lung disease were reviewed as the baseline CT in terms of radiographic extents (laterality and number of involved lobes) and disease patterns (ie, either nodular bronchiectatic or fibrocavitary type) [14, 18] .
Diagnosis of NTM Lung Disease
Patients were diagnosed with M. abscessus complex lung diseases based on the diagnostic criteria of the American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guideline [18] . 
Treatment and Response Assessment
Patients underwent follow-up every 3-6 months and treatment was offered in cases of significant radiographic progression (ie, new cavity formation), or worsening respiratory symptoms (ie, development of hemoptysis). For this study, patients were defined as having disease progression if treatment was offered to them. Once patients had agreed on a course of treatment, they were hospitalized and central catheters were peripherally inserted for long-term parenteral therapy. Patients received combination antibiotic therapy including 1 macrolide agent (clarithromycin or azithromycin) and at least 2 parenteral agents such as amikacin, cefoxitin, or imipenem.
Patients were hospitalized for at least 3 weeks and the decision whether to discharge was made by the duty physician. After patient discharge, macrolide treatment was continued with concurrent outpatient parenteral antibiotic therapy comprising amikacin 3 or 5 times a week via peripherally inserted central catheters. The duration of amikacin administration was not predefined and patients continued to receive amikacin until either clinical improvement or the development of significant adverse events was observed.
Culture conversion was defined as the production of 3 consecutive negative cultures from sputum specimens. If patients could not expectorate sputum after 1 or 2 consecutive negative cultures, they were also regarded as having culture conversion. Final treatment responses were classified as either sustained culture conversion or as treatment failure. Treatment failure included failure of achieving culture conversion, or recurrence after initial culture conversion. If patients could not be followed up before culture conversion, they were regarded as having treatment failure.
Statistical Analysis
Data were summarized as means with standard deviations for continuous variables with normal distribution, or medians with interquartile range (IQR) for those with nonnormal distribution. For categorical variables, values were reported as frequencies and proportions. Differences between groups were analyzed using Student t test, Mann-Whitney test, Pearson χ 2 test, or Fisher exact test, as appropriate. P values <.05 were considered statistically significant in a 2-tailed test.
Time to progression was compared between patients with M. abscessus and M. massiliense lung diseases using the KaplanMeier method. To elucidate risk factors for progression, multivariable logistic regression was performed. Among patients who started treatment, a comparison of the time to initial culture conversion between patients with M. abscessus and M. massiliense lung diseases was performed using the KaplanMeier method. Multivariable logistic regression was also used to determine predictors of sustained culture conversion. In both logistic regression models, variables with P values <0.1 in the univariable analysis were included in the multivariable analysis, and adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were calculated.
In addition, we performed mediation analysis to evaluate whether susceptibility to clarithromycin could explain the different treatment outcomes observed for M. abscessus and M. massiliense lung disease (Supplementary Figure 1) [24] . Binary mediation with bootstrapping (500 replications) was used to estimate the direct effect (effect of the predictor on the outcome by itself) and the indirect effect (effect of the predictor on the outcome via the mediator) with CIs, as described in previous studies of similar design [25] . Where the CI of the indirect effect does not cross zero, such analysis can provide evidence of significant mediation. We also adjusted the model by including other variables significantly associated with sustained culture conversion as covariates. All the statistical analyses were carried out using Stata software version 14.0 (StataCorp LP, College Station, Texas).
RESULTS
Characteristics of Patients
During the study period, a total of 113 patients with M. abscessus complex lung diseases were identified. They were classified into 3 predefined groups: 56 patients had M. abscessus lung diseases, 54 patients had M. massiliense lung diseases, and the remaining 3 patients had M. abscessus/M. massiliense mixed lung diseases. These 3 patients were not included in the main analyses of the current study.
The median age of patients with M. abscessus lung diseases and those with M. massiliense lung diseases was similar at 64 and 63 years, respectively (P = .990). The proportion of female patients was also similar (66.1% vs 63.0%, respectively; P = .733). Less than one-fifth of patients (17.9% of M. abscessus and 18.5% of M. massiliense) showed a fibrocavitary pattern of disease. MAC was the most common species of co-infected NTM (21 of 23 in the M. abscessus group and 15 of 17 in the M. massiliense group) ( Table 1) .
In Vitro Drug Susceptibility
The results of an in vitro antimicrobial susceptibility test were available for 95 patients ( (Table 4) .
Patients with M. massiliense lung diseases were significantly more likely to achieve initial culture conversion (Figure 1 ; P = .045). However, recurrence occurred in 6 of 11 patients with M. abscessus lung disease who achieved initial culture conversion, whereas no recurrence was observed in 14 patients with .69]) was identified as a negative predictor. However, the use of parenteral agents was not associated with sustained culture conversion ( Table 5 ).
In the mediation analysis, we tested the susceptibility to clarithromycin as a mediator because it differed between the 2 groups and was associated with treatment outcomes. We adjusted the mediation analysis model with the BMI and the use of azithromycin rather than clarithromycin. The effect of infection with M. abscessus or M. massiliense on the treatment outcome was shown to be significantly mediated by the susceptibility of the isolated strain to clarithromycin (indirect effect, 0.28 [CI, .08-.95]). The proportion of the indirect effect to the total effect was 38.1%.
DISCUSSION
The comparison of M. abscessus and M. massiliense lung diseases in our study revealed several interesting findings. First, the disease progression rate did not differ between the 2 groups during the follow-up period. Instead, lower BMI, bilateral lung involvement, and fibrocavitary-type disease were predictive of disease progression. Second, better treatment response was observed for M. massiliense lung diseases, which is consistent with previous reports [13, 15, 16] . It is worth noting that this difference in treatment outcomes between M. abscessus and M. massiliense lung diseases was only partly mediated by their different susceptibilities to clarithromycin. Third, azithromycin showed superior efficacy in achieving sustained culture conversion compared with clarithromycin.
The natural history of NTM lung diseases remains elusive, which makes it difficult to decide when to initiate treatment [26] . Mycobacterial virulence and host factors influence the progression of NTM lung diseases [18] . For MAC lung diseases, patients with M. intracellulare lung diseases were reported to be more likely to receive antibiotic therapy and have unfavorable microbiologic response after treatment compared with those with M. avium lung diseases [27] . However, our study showed no difference in disease progression rate between M. abscessus and M. massiliense lung diseases, which suggests that these 2 species may not differ in virulence despite their difference in treatment response. Instead, clinical characteristics such as lower BMI and the radiographic pattern of involvement appear to be associated with disease progression. These findings are similar to those reported for MAC lung diseases [28] [29] [30] .
For patients who received treatment for M. abscessus complex lung diseases, patients infected with M. massiliense rather than M. abscessus were more likely to have sustained culture conversion, which was consistent with previous studies [13, 15, 16] . It has been suggested that the better treatment response observed for M. massiliense lung diseases is attributable to M. massiliense isolates rarely having inducible resistance to clarithromycin, and their more frequent susceptibility to macrolides [12, 15, 31] . However, according to the mediation analysis carried out in our study, this difference in susceptibility to clarithromycin accounted for only about 40% of the difference in treatment outcomes. This means that microbiologic factors other than susceptibility to clarithromycin as well as host factors influence treatment outcomes. Whole-genome sequencing and analysis of the causative mycobacteria could therefore play a role in identifying additional markers that may help to explain the different treatment outcomes observed between the 2 species.
We determined several factors, including BMI and choice of macrolide, that influenced treatment outcomes. Lower BMI is a well-known factor associated with the development and/or progression of various chronic lung diseases and several infectious diseases [32] [33] [34] . However, our study is the first to report the superiority of azithromycin to clarithromycin in terms of achieving sustained culture conversion in patients with M. abscessus complex lung diseases. In MAC lung diseases, no difference was reported in treatment efficacy between these 2 drugs [35] . The reasons why azithromycin showed better response in our study is unclear, but the superiority of azithromycin in preventing inducible resistance may provide an explanation [31] . However, another study found no difference in terms of inducible resistance between these 2 agents, leaving some controversy around this issue [12] . Another possible explanation may lie in the different anti-inflammatory or immunomodulatory effects of these macrolides, but these pharmacologic differences have not been consistent in previous reports [36, 37] . The longer half-life and improved tissue penetration of azithromycin could also explain the higher treatment efficacy of this drug [38] .
Although the ATS/IDSA guideline recommended the use of parenteral agents as well as macrolide treatment [18] , in our study, the use of parenteral agents did not increase the chance of achieving sustained culture conversion. Longer treatment periods with parenteral agents than those used in our study may be needed to improve outcomes. However, such longer treatment periods would be impractical because of adverse drug reactions, inconvenience to patients, and increased costs. The observation that 4 of 7 patients (all 4 patients with M. massiliense lung diseases) for whom azithromycin or clarithromycin was prescribed without parenteral agents achieved sustained culture conversion also raises a question on the role of using parenteral agents, especially for M. massiliense lung diseases. A recent report showing no difference in treatment outcome between shorter and longer use of parenteral agents for the treatment of M. massiliense lung diseases further emphasizes this issue [39] .
The current study has several limitations. First of all, the initiation of treatment was determined by the duty physician. Abbreviations: AFB, acid-fast bacilli; BMI, body mass index; CI, confidence interval; NTM, nontuberculous mycobacteria. a All variables with a P value <.1 following univariable analysis were subjected to multivariable logistic regression, with the exception of susceptibility to clarithromycin. Instead, the susceptibility to clarithromycin was evaluated as a mediator. b At initiation of treatment.
Although this decision was made taking account of radiographic and symptomatic changes, the subjective judgment of the physicians may have introduced bias. Second, several patients refused admission and did not receive parenteral therapy. Although this introduced variations to the predefined treatment protocol, it also enabled us to compare treatment response between patients who received parenteral therapy with those who did not. Third, only microbiologic response was assessed as a treatment outcome in this study. Considering the chronic course of disease, improvement in patient quality of life as well as their length of survival may be more appropriate treatment response targets for M. abscessus complex lung diseases, as was illustrated by a recent study [40] . Finally, the small number of patients included in this study limited the statistical power of the analysis. A nationwide multicenter study should be performed to provide more reliable results.
In conclusion, the progression rates of M. abscessus lung diseases and M. massiliense lung diseases were similar, but treatment outcomes were better for patients with M. massiliense lung diseases. Lower BMI, bilateral lung involvement, and fibrocavitary-type disease were identified as predictors of disease progression. Among those patients who underwent treatment, infection with M. massiliense rather than M. abscessus and the use of azithromycin rather than clarithromycin were associated with sustained culture conversion. The difference in treatment outcomes observed for these 2 species was partly mediated by their difference in susceptibility to clarithromycin.
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